the invention relates to the medical biotechnology and is a way to obtain \u0438\u043d\u0430\u043a\u0442\u0438\u0432\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0439 \u0446\u0435\u043b\u044c\u043d\u043e\u0432\u0438\u0440\u0438\u043e\u043d\u043d\u043e\u0439 \u0433\u0438\u0434\u0440\u043e\u043e\u043a\u0438\u0441\u044c\u0430\u043b\u044e\u043c\u0438\u043d\u0438\u0435\u0432\u043e\u0439 vaccine to in the pandemic influenza a \/ h5n1 from with strain a \/ AstanaRG \/ 6: 2 \/ 2009 obtained by reverse genetics in \u043d\u0438\u0438\u043f\u0431\u0431 kn mes rk for the development of \u043f\u0430\u043d\u0434\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0439 vaccine.the essence of the invention is to obtain \u0438\u043d\u0430\u043a\u0442\u0438\u0432\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0439 \u0446\u0435\u043b\u044c\u043d\u043e\u0432\u0438\u0440\u0438\u043e\u043d\u043d\u043e\u0439 \u0433\u0438\u0434\u0440\u043e\u043e\u043a\u0438\u0441\u044c\u0430\u043b\u044e\u043c\u0438\u043d\u0438\u0435\u0432\u043e\u0439 vaccine against influenza a \/ h5n1 is \u043e\u043f\u0442\u0438\u043c\u0430\u043b \u044c\u043d\u044b\u0439 (gentle) regime in \u0444\u043e\u0440\u043c\u0430\u043b\u0438\u043d\u043e\u043c at concentrations of 0.05%, further purified and concentrated by chromatography based filtration methods and use \u0437\u043e\u0432\u0430\u043d\u0438\u0435\u043c new with strain a \/ AstanaRG \/ 6: 2 \/ 2009the method of reverse genetics in \u043d\u0438\u0438\u043f\u0431\u0431 kn mes rk, and immunologic adjuvant, aluminum hydroxide is added. the invention provides \u043f\u0430\u043d\u0434\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0439 vaccine for the prevention of influenza a \/ h5n1, with a high degree of purification of the virus, and therefore, with improved securit awn and \u0438\u043c\u043c\u0443\u043d\u043e\u0433\u0435\u043d\u043d\u043e\u0441\u0442\u044c\u044e, manufacturing process which is more \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0447\u043
